PDCD1 and melanoma: The global, randomized, double-blind, phase II/III RELATIVITY-047 (CA224-047) trial is the first first-line treatment study to demonstrate that dual inhibitory effects of LAG-3, and the PD-1 pathways may be a key target to enhance the immune response and help improve the prognosis of patients with metastatic or unresectable melanoma (15).